From “blockbusters” to “biosimilars”: An opportunity for patients, medical specialists and health care providers

Advances in basic research and research and development plans of pharmaceutical companies are radically changing the kind of available drugs and therapeutic targets. We are switching from predominantly chemical molecules, aimed at treating large populations of patients (blockbuster drugs), to a new...

Ausführliche Beschreibung